Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer

The majority of breast cancers are oestrogen-receptor-positive (ER+) and are subject to endocrine therapy; however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. The SLC7A5/SLC3A2 complex is a major route for the transport of large neutral essential amino acids through the plasma membrane. Alterations in the expression and function of those amino-acid transporters lead to metabolic reprogramming, which contributes to the tumorigenesis and drug resistance. This study aims to assess the effects and roles of SLC7A5/SLC3A2 co-expression in predicting responses to endocrine therapy in patients with ER+ breast cancer. The biological and clinical impact of SLC7A5/SLC3A2 co-expression was assessed in large annotated cohorts of ER+/HER2− breast cancer with long-term follow-up at the mRNA and protein levels. In vitro experiments were conducted to investigate the effect of SLC7A5/SLC3A2 knockdown in the proliferation of cancer cells and to the sensitivity to tamoxifen. We found that proliferation-related genes are highly expressed in a subgroup of patients with high SLC7A5/SLC3A2, and knockdown of SLC7A5/SLC3A2 decreased proliferation of ER+ breast cancer cells. In patients treated with endocrine therapy, high SLC7A5/SLC3A2 co-expression was associated with poor patient outcome, and depletion of SLC7A5/SLC3A2 using siRNA increased the sensitivity of breast cancer cells to tamoxifen. On the basis of our findings, SLC7A5/SLC3A2 co-expression has the potential of identifying a subgroup of ER+/HER2− breast cancer patients who fail to benefit from endocrine therapy and could guide the choice of other alternative therapies.

[1]  Xin Zhao,et al.  Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex , 2019, Nature.

[2]  A. Gavin,et al.  Cell metabolism regulates integrin mechanosensing via an SLC3A2-dependent sphingolipid biosynthesis pathway , 2018, Nature Communications.

[3]  M. Hediger,et al.  Amino acid transporters revisited: New views in health and disease. , 2018, Trends in biochemical sciences.

[4]  A. Green,et al.  Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer , 2018, Histopathology.

[5]  W. Sauerbrei,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration , 2018, Journal of the National Cancer Institute.

[6]  I. Ellis,et al.  The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours , 2018, Breast Cancer Research.

[7]  I. Ellis,et al.  The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes , 2018, British Journal of Cancer.

[8]  I. Ellis,et al.  Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations , 2018, Histopathology.

[9]  K. Guan,et al.  Differential regulation of mTORC1 by leucine and glutamine , 2015, Science.

[10]  Tomoya Mizuno,et al.  Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma , 2013, BMC Cancer.

[11]  M. Malumbres,et al.  HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. , 2012, Molecular cell.

[12]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[13]  T. Tamiya,et al.  Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas , 2012, BMC Clinical Pathology.

[14]  J. Horiguchi,et al.  Correlation of L‐type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis , 2012, Cancer science.

[15]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[16]  Y. Kanai,et al.  L‐type amino‐acid transporter 1 as a novel biomarker for high‐grade malignancy in prostate cancer , 2009, Pathology international.

[17]  N. Sunaga,et al.  Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer , 2008, British Journal of Cancer.

[18]  G. Prager,et al.  CD98hc (SLC3A2) Interaction with the Integrin β Subunit Cytoplasmic Domain Mediates Adhesive Signaling* , 2007, Journal of Biological Chemistry.

[19]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[20]  Y. Kanai,et al.  Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. , 2001, Biochimica et biophysica acta.

[21]  S. Kimball,et al.  Regulation of translation initiation by amino acids in eukaryotic cells. , 2001, Progress in molecular and subcellular biology.

[22]  T. Masuko,et al.  Transformation of BALB3T3 cells caused by over‐expression of rat CD98 heavy chain (HC) requires its association with light chain: Mis‐sense mutation in a cysteine residue of CD98HC eliminates its transforming activity , 2000, International journal of cancer.

[23]  K. Tomita,et al.  4F2 (CD98) Heavy Chain Is Associated Covalently with an Amino Acid Transporter and Controls Intracellular Trafficking and Membrane Topology of 4F2 Heterodimer* , 1999, The Journal of Biological Chemistry.

[24]  C. Shoemaker,et al.  Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family , 1998, Nature.